A direct-to-patient (DtP) clinical trial design, where investigational medicinal products (IMP) and clinical supplies are shipped or delivered directly to patients, fits within a decentralized clinical trial (DCT) model. Although patients, sites, and sponsors can all benefit from this trial design, there are unique complexities to DtP trials, that can be managed with advanced technology. In this podcast, Jon Paras talks about this trial strategy, the unique challenges, what the industry is doing to address these challenges and how technology can help facilitate adoption of this trial design.
Listen to the podcast to learn more about why a sponsor would want to adopt a direct-to-patient clinical trial strategy and the benefit to patients.
